Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Fever management practices among sickle cell disease programs in low and middle-income countries
source: American Society of Pediatric Hematology/Oncology
year: 2016
authors: Catherine Taylor, Alexandra Coria, Venée N. Tubman
summary/abstract:Under-5 mortality for children with sickle cell disease (SCD) in low and middle-income countries (LMIC) is high, with the majority of deaths likely related to infectious complications. In the United States, dramatic decreases in childhood mortality for SCD over the past 40 years have been aided by interventions to reduce mortality associated with infections. In LMIC, these interventions (i.e. penicillin prophylaxis, rapid investigation and treatment of febrile illness, and vaccination) may not be consistently available.
Design/Method: A survey of English and French-speaking providers at SCD programs in LMIC. The survey was available online and offline, distributed via email distribution lists, at applicable meetings, and by referral.
Results: Providers from 13 LMIC returned 27 interpretable surveys, including 23 from malaria-endemic areas. Newborn screening is associated with 34% (n=10/27) of programs. Pneumococcal conjugate vaccine is available at 66% (n=14/25) of programs. Penicillin prophylaxis is prescribed to some or all patients by 65% (n=17/26) of respondents. Malaria prophylaxis is prescribed by 83% (n=19/23) in malarial-endemic areas. Forty-eight percent of programs (n=14/27) have written fever management protocols. To patients with SCD presenting with fever, 21% (n=5/24) of respondents ‘always’ give antibiotics, although 54% (n=13/24) give antibiotics ‘almost always’. First line antibiotics are given orally by 27% (n=7/26); 77% (n=20/26) would consider oral antibiotics in some circumstances. The preferred first line antibiotic is ceftriaxone for 9/19 giving IV/IM antibiotics and amoxicillin-clavulanate for 4/7 giving oral antibiotics. At programs in malaria-endemic areas, 79% (n=18/23) ‘always’ or ‘almost always’ give antimalarials to febrile patients. Forty-six percent (n=12/26) of respondents report that a majority of febrile patients receive antibiotics prior to presentation. In malaria-endemic areas, 74% (n=17/23) report that a majority receive antimalarials prior to presentation.
read moreRelated Content
-
Initial results from a cohort in a phase 2a study (GBT440-007) evaluating adolescents with sickle cell disease treat...Background: Sickle cell disease (SCD), ...
-
Social Media Discussions Provide new Insight About Perceptions of Hydroxyurea in the Sickle Cell CommunityHydroxyurea (HU) has proven efficacious ...
-
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell DiseaseMaxCyte, a US-based global company dedic...
-
Patients With Sickle Cell Disease may Have Lower Risk for C. DifficileFindings from a retrospective cohort stu...
-
Sickle Cell Retinopathyhttps://www.youtube.com/watch?v=tCgAHWvV...
-
Novartis acquires US pharma research firm Selexys PharmaceuticalsSwiss-based pharmaceuticals giant Novart...
-
CTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell DiseaseThe U.S. Food and Drug Administration (F...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.